

## Blood Group Genotyping in a Population of Highly Diverse Ancestry

Jordão Pellegrino Jr.,<sup>1\*</sup> Lilian Castilho,<sup>1</sup> Maria Rios,<sup>2</sup> and Cármino A. De Souza<sup>1</sup>

<sup>1</sup>Hemocentro Unicamp, Campinas, SP, Brazil

<sup>2</sup>New York Blood Center, New York, New York

Accurate phenotyping of red blood cells (RBCs) can be difficult in transfusion-dependent patients such as those with thalassemia and sickle cell anemia because of the presence of previously transfused RBCs in the patient's circulation. Recently, the molecular basis associated with the expression of many blood group antigens was established. This allowed the development of a plethora of polymerase chain reaction (PCR)-based tests for identification of the blood group antigens by testing DNA. The new technologies complement phenotyping and overcome some of the limitations of hemagglutination assays. These molecular assays were developed on the basis of DNA sequences of individuals of Caucasian ancestry. The present study addresses the concern that these genotyping assays may not be appli-

cable to populations of highly diverse ancestry because of variability in intronic regions or because of unrecognized alleles. We determined both phenotype and genotype for *RHD*, *K1/K2*, *JKA/JKB*, *FYA/FYB*-GATA in 250 normal blood donors using PCR. Phenotype and genotype results agreed in 100% of the cases, indicating that molecular genotyping protocols can be effectively applied to populations with a highly diverse genetic background. However, genotyping for Duffy antigens provided information that could not be obtained by phenotyping. Essentially, 30.5 % of the donors with the *FYB* gene typed as Fy(b-) because of mutations in the GATA box. This information is very useful for the management of transfusion dependent patients. *J. Clin. Lab. Anal.* 15:8–13, 2001. © 2001 Wiley-Liss, Inc.

**Key words:** genotyping assays; blood group antigens; transfusion-dependent patients; Brazilian population; hemagglutination

### INTRODUCTION

Alloantibodies to blood group antigens are clinically important in the immune destruction of red blood cells (RBCs) in allogeneic blood transfusions, feto-maternal incompatibility, autoimmune anemias, and organ transplantation (1). The detection of blood groups antigens and identification of alloantibodies by hemagglutination assays contribute significantly to blood transfusion practice and to the management of pregnancies at risk of hemolytic disease of the newborn (2). Accurate immunohematologic evaluation is critical for the safety of transfusion-dependent patients including those with sickle cell disease, thalassemia, autoimmune hemolytic anemias, and aplastic anemias. The incidence of alloimmunization to RBC antigens is particularly high in these patients (3–11). Sensitized patients receive antigen-matched RBC transfusions. In some programs, patients in need of chronic transfusion receive antigen-matched RBC transfusions in order to prevent alloimmunization. There is no consensus among different institutions about the selection of antigens negative units for the prevention of alloimmunization (12–14). In our institution matching includes, in ad-

dition to ABO, phenotyping for Rh, Kell, Duffy, and Kidd. Phenotyping of these patients and of patients that received massive transfusions can be time-consuming and hard to interpret because of the presence of donor RBCs in the recipient's circulation.

Molecular biological approaches to the study of blood group antigens have elucidated the molecular bases of most blood group alleles and phenotypes. These technologies have been applied to clinical settings and complement classical hemagglutination techniques in the clinical laboratory (15–18). However, most of the primer sets that we have developed for molecular genotyping were based on sequences of one or few individuals, usually of Caucasian origin, and in-

Grant sponsor: Fundação de Amparo à Pesquisa do Estado de São Paulo; Grant number: FAPESP 99/03620-0.

\*Correspondence to: Jordão Pellegrino Jr., Hemocentro, Unicamp Rua Carlos Chagas, 480 Caixa Postal 6198, CEP 13081-970 Barão Geraldo, Campinas, SP, Brazil. E-mail: jordao@mpcnet.com.br

Received 27 April 2000; Accepted 28 July 2000

clude at least one primer in intronic region of the gene (19–23). The present study addresses the concern that these genotyping assays may not be applicable to populations of highly diverse ancestry because: (1) at least one of the primers used in these assays is located in intronic sequences, and there may be less evolutionary pressure to preserve introns than exons; and (2) miscegenation (genetic mixture) may facilitate the generation of new alleles (24).

The Brazilian population is of heterogeneous ethnical origin. This diverse population is also unevenly distributed within a country of continental dimensions. In addition to the Native American population, Brazil is home to immigrants from Portugal, Italy, Spain, Germany, Japan, and the Middle East. During the slave trade from the 16<sup>th</sup> to the 18<sup>th</sup> century approximately 4 million Africans, mainly from Angola, Congo, and Mozambique, settled in almost all regions of Brazil (25). The intense process of miscegenation made the Brazilian population unique in its ethnic background. The region of Southeastern Brazil is the most populated, has continuously received immigrants from Northeastern Brazil, and is characterized by a high degree of admixture between descendants of Europeans, Africans, and Native Americans. Blood donors from this region constitute a representative sample of a genetically diverse population.

We found that the new molecular technologies can be safely applied to the genetically diverse population of Brazil. We also observed that, in the case of Duffy antigens, molecular genotyping can contribute substantially to transfusion management because of the high prevalence of *FYB* individuals with a mutated GATA box preventing its expression on RBCs.

## MATERIALS AND METHODS

### Blood Samples

The studies were performed on blood samples from 250 blood donors to the Hemocentro Unicamp. All agreed to participate in this study and signed an informed consent. The donors selected had donated at least three times in the past and been phenotyped for Rh, Kell, Kidd, and Duffy blood group antigens.

### Agglutination Tests

Phenotypes were determined by hemagglutination in gel cards (Diamed AG, Morat, Switzerland) using two sources of antibodies.

### DNA Preparation

DNA was extracted from blood samples using the Easy DNA Kit (Invitrogen, Carlsbad, CA) according to the manufacturer's recommendations. The DNA preparations were analyzed for quality by agarose gel electrophoresis and quantified by measurement of optical density at 260 nm.

## Polymerase Chain Reaction (PCR) Amplification

The primers and amplification conditions were previously described (17,18). Briefly, PCR was performed with 100–200 ng of DNA, 50 pmols of each primer, 2 nmols of each dNTP, 1.0 U *Taq* DNA polymerase and buffer in a final volume of 50  $\mu$ l. The PCR profile in the thermal cycler (480, Perkin Elmer, Foster City, CA) was used for all assays as follows: 15 minutes at 95°C, 35 cycles of 40 seconds at 94°C, 40 seconds at 62°C, and 1 minute at 72°C, followed by 10 minutes at 72°C. Amplified products were subjected to electrophoresis in 1.5% agarose gel in Tris-Acetate EDTA buffer (TAE), to verify amplification efficiency before treatment with restriction enzymes.

The PCR analysis for the presence of *RHD* was performed in two genomic regions, intron 4 and exon 10, as previously described (18). For intron 4, a primer set (RHI41/RHI42/RHI43) yielded a product of 115 bp for *RHD* and 236 bp for *RHCE*. For exon 10, a common 5' primer (EX10F) was used for both *RHD* and *RHCE*. When paired with the *RHD*-specific 3'-untranslated region (UT) primer (RHD3UT), it produced a product of 245 bp, and when paired with the *RHCE*-specific 3'-UTR (RHCE3UT), it yielded a product of 160 bp (Fig. 1).

## RFLP Analysis


Analysis of results was performed under code without knowledge of phenotype test results. PCR-amplified products were digested overnight with the appropriate restriction enzymes (MBI Fermentas, Amherst, NY or New England Biolab, Beverly, MA), in a final volume of 20  $\mu$ l using 10  $\mu$ l of amplified product and enzyme in 1x buffer according to manufacturer's instructions.

*Bsm*I, *Mnl*I and *Ban*I enzymes were used to determine, *K1/K2* (698C > T), *JK A/JK B* (838A > G) and *FY A/FY B* (125 G > A; 265 C > T; 298 G > A) (17–20,24,26), respectively (Figs. 2, 3, 4). Furthermore, the *Sty*I enzyme was used to distinguish between normal and mutated GATA-1 binding motif (–33T > C), because the G > ATA-1 binding site is critical for Duffy protein expression in the red cell membrane (21,22,27–29). The RFLP analyses were performed after electrophoresis in 3% agarose in TAE or 8% polyacrylamide gel (PAGE) in Tris-Borate-EDTA.

## RESULTS

There was complete agreement between phenotype and genotype for Rh, Kell, and Kidd in the studied population of Brazilian blood donors with highly diverse ancestry. Thus, the PCR primer sets worked adequately for the determination of genotypes despite the use of primers designed to hybridize with intronic regions of sequences obtained from Caucasians. Results are summarized in Table 1.

The genotyping approach for Rh, Kell, and Kidd was straightforward. Of the 250 blood donors samples, 207



**Fig. 1.** Picture of 1.2% agarose gel subjected under UV after electrophoresis of PCR products. Lanes 1–3, PCR products amplified with RHI41/RHI42/RHI43 primer set; lanes 1 and 3, *RH D* positive samples 1 and 3 display bands of 236 bp for *RH CE* and 115 bp for *RH D* intron 4 sequence; lane 2, *RH D* negative sample 2 displays only the 236-bp band corresponding to *RH CE* intron 4 sequence; lane 4, reaction blank; lane 5, 50-bp DNA ladder; lanes 6–

8, showing PCR products amplified with primer set EX10F/RHD3'-UTR/RHCE3'-UTR; lanes 6 and 8, *RH D* positive samples 6 and 8 display bands of 245 bp for *RH D* and 160 bp for *RH CE* exon 10 sequence; lane 7, *RH D* negative sample 7 displays only the 160 bp band corresponding to *RH CE* exon 10 sequence.


phenotyped as RhD<sup>+</sup> and were also positive for *RH D* in both intron 4 and exon 10/3'UTR (e.g., they had amplified products for both *RH D* and *RH CE* sequences). The 43 samples phenotyped as RhD<sup>-</sup> were also genotyped as *RH D*-negative in both intron 4 and exon 10/3'UTR (e.g., they had amplified from *RH CE*, but not from *RH D* sequences) (Table 1, Fig. 1). Complete correlation between genotype and phenotype was also observed in Kell (Table 1, Fig. 2) and Kidd (Table 1, Fig. 3).

The correlation between Duffy phenotype and genotype confirmed previous observations showing that a substantial


number of individuals with *FY B* genotype do not express this antigen on the surface of RBCs (Table 1). Thus, appropriate correlation between genotype and phenotype required complete analysis of the *FY* polymorphisms 125 G > A (*FY A/FY B*), 265C > T/298G > A (associated with Fy<sup>x</sup> phenotype), and analysis of mutations in the GATA box (-33 T > C). The Duffy protein is absent from the erythroid lineage of individuals with mutated GATA box (27–29). There is a high prevalence of GATA mutation associated with the *FY B* allele. Sixty-six (30.5%) of the 216 samples with *FY B* genotype had mutated GATA box and were phenotyped as Fy(b-). Three of the donors had the phenotype Fy(b-) and the mutations associated with Fy<sup>x</sup> (Table 1). Phenotypically, Fy<sup>x</sup> is characterized by weak expression of *FY B* that can only be detected using potent anti-Fy<sup>b</sup> reagent (26,30). Unfortunately, reagents capable of detecting Fy<sup>x</sup> were not available. Fy(a-b-) were *FY B/FY B* heterozygous GATA mutation and had both 265C > T and 298G > A.

## DISCUSSION

Our study demonstrated that the PCR primers for Rh, Kell, Kidd, and Duffy that were designed according to genomic sequences of individuals of Caucasian ancestry and included sequences of intronic regions could be used for blood group genotyping of populations of highly diverse ancestry. There was complete agreement between phenotype and genotype for RhD, Kell, and Kidd antigens. In the case of Duffy, 66 (30.5%) of the 216 specimens that were genotyped as *FY B* were phenotyped as Fy(b-), emphasizing the importance of the analysis of the GATA box in these populations. In the




**Fig. 2.** Picture of RFLP analysis of PCR products amplified with KEL S/KEL R primer set using *Bsm* I after electrophoresis in 8% acrylamide gel. Lane 1, 100-bp DNA ladder; lane 2, undigested PCR product; lanes 3 and 4, samples 1 and 2, *K 2/K 2* homozygous; lane 5, sample 3, *K 1/K 2* heterozygous; lane 6, sample 4, *K 2/K 2* homozygous.



**Fig. 3.** Picture of RFLP analysis of PCR products amplified with JK1S/JK2 primer set using *Mnl* I after electrophoresis in 8% acrylamide gel. Lane 1, 100-bp DNA ladder; lane 2, undigested PCR product; lane 3, sample 1, *JK A/JK B* heterozygous; lane 4, sample 2, *JK B/JK B* homozygous; lane 5, sample 3, *JK A/JK A* homozygous.

presence of normal GATA-1 binding motif (nt -33 T) and normal expression of *FY B* (nt 265 C), phenotype and genotype agreed. When the GATA-1 motif is mutated, or *FY B* had  $Fy^x$  sequence (nt 265 T), a pseudo-discrepancy is observed because of the absence or weakening of *FY* gene expression in the erythroid lineage (26,29,30). Expression of the *FY B* gene in other body tissues is normal and these individuals do not make anti-

bodies to  $Fy(b+)$ . Thus, patients with  $Fy(b-)$  phenotype and *FY B* genotype with mutated GATA box can be transfused with  $Fy(b+)$  RBCs without the risk of alloimmunization. The combined use of genotyping and hemagglutination reduces the need for  $Fy(b-)$ , a phenotype present in only one third of the Brazilian blood donors. Sixty-six (66%) of the 100  $Fy(b-)$  donors identified in this study could theoretically receive  $Fy(b+)$  RBCs.



**Fig. 4.** A, RFLP analysis of PCR products amplified with FYAB1/FYAB2 primer set using *Ban* I after electrophoresis in 3% agarose gel. Lane 1, 100-bp DNA ladder; lane 2, undigested PCR product; lane 3, sample 1, *FYA/FY B* heterozygous; lane 4, sample 2, *FYA/FY A* homozygous; lane 5, sample 3, *FY B/FY B* homozygous. B, RFLP analysis of PCR products amplified

with FYN1/FYN2 primer set using *Sty* I after electrophoresis in 8% acrylamide gel for detection of GATA mutation. Lane 1, 100-bp DNA ladder; lane 2, undigested PCR product; lane 3, sample 1, homozygous for GATA mutation; lane 4, sample 2, homozygous wild type.



**TABLE 1. Phenotyping and genotyping results for *RH D*, *K 1/K 2*, *JKA/JKB*, and *FYA/FYB-GATA* on samples from 250 blood donors**

Genotype	Phenotype			
	RhD+	RhD-		
Rh system				
RHD+/RHCE+	207	0		
RHD -RHCE+	0	43		
Kell system				
K1K2	227	0		
K2K2	0	23		
Kidd system				
Jk(a+b-)			Jk(a+b+)	Jk(a-b+)
JKA/JKA	54	0	0	
JKA/JKB	0	161	0	
JKB/JKB	0	0	35	
Duffy system				
Fy(a+b-)			Fy(a+b+)	Fy(a-b+)
FYA/FYB (T/T)	0	68	0	0
FYA/FYB (T/C)	28	0	0	0
FYB/FYB (T/T)	0	0	82	0
FYB/FYB (T/C)	0	0	0	3 <sup>a</sup>
FYB/FYB (C/C)	0	0	0	35

<sup>a</sup>Fy<sup>x</sup> 265T, 298A.

The determination of blood group polymorphism at the genomic level facilitates the resolution of clinical problems that cannot be addressed by hemagglutination. They are useful to: (1) determine antigen types for which currently available antibodies are weakly reactive; (2) type patients who have been recently transfused; (3) identify fetuses at risk for hemolytic disease of the newborn; and (4) to increase the reliability of repositories of antigen negative RBCs for transfusion.

It is important to note that PCR-based assays are prone to different types of errors than those observed with hemagglutination assays. For instance, contamination with amplified products may lead to false positive test results. In addition, the identification of a particular genotype does not necessarily mean that the antigen will be expressed on the RBC membrane. This complexity is exemplified by the existence of genes that silence mutations in locations other than that being analyzed (e.g., point mutation in the GATA box), by genes that are silenced by the a gene-encoding protein with modifying effect (e.g., Rh<sub>mod</sub>, Rh<sub>null</sub>), and by the detection or lack of detection of a hybrid gene (31–34).

Transfusion-dependent patients have sickle cell disease, thalassemias, and aplastic anemias, and frequently become alloimmunized. Blood group genotyping contributes substantially to the safety of blood transfusion in these recipients. Although it is unlikely that molecular genotyping will replace hemagglutination any time in the near future, together these techniques have substantial value in the resolution of clinical laboratory problems, and consequently in the quality of patient care.

## ACKNOWLEDGMENTS

We thank Roberta Violati and Kim Hue Roye for technical assistance. We are also grateful to Dr. Celso Bianco for his critical review of the manuscript and to Dr. Nelson F. Mendes for his support.

## REFERENCES

1. Issitt P, Anstee DJ. Applied blood group serology, 4<sup>th</sup> ed. Durham, North Carolina: Montgomery Scientific Publications; 1998.
2. Mollison PL, Engelfriet CP, Contreras M. Blood Transfusion in clinical medicine, 9<sup>th</sup> ed. Oxford, England: Blackwell; 1993.
3. Blumberg N, Peck K, Ross K, Avila E. Immune response to chronic red blood cell transfusion. Vox Sang. 1983;44:212–217.
4. Orlina AR, Unger PJ, Koshy M. Post-transfusion alloimmunization in patients with sickle cell disease. Am J Hematol 1978;5:101–106.
5. Coles SM, Klein HG, Holland PV. Alloimmunization in two multitransfused patient populations. Transfusion 1981;21:462–466.
6. Davies SC, McWilliam AC, Hewitt PE, Devenish A, Brozovic M. Red cell alloimmunization in sickle cell disease. Br J Haematol 1986;63:241–245.
7. Reisner EG, Kostyu DD, Philips G, Walker C, Dawson DV. Alloantibody response in multiply transfused sickle cell patients. Tissue Antigens 1986;30:161–166.
8. Cox JV, Steane E, Cunningham G, Frenkel EP. Risk of alloimmunization and delayed hemolytic transfusion reactions in patients with sickle cell disease. Arch Intern Med 1988;148:2485–2489.
9. Rosse WF, Gallagher D, Kinney TR. Transfusion and alloimmunization in sickle cell disease. Blood 1990;76:1431–1437.
10. Vichinsky EP, Earles A, Johnson RA, Hoag MS, William A, Lubin B. Alloimmunization in sickle cell anemia and transfusion of racially unmatched blood. N Engl J Med 1990;322:1617–1621.
11. Giblett ER. A critique of the theoretical hazard of inter-vs-intra-racial transfusion. Transfusion 1961;1:233–238.
12. Tahhan RH, Holbrook LR, Braddy LR, Brewer LD, Christie JD. Antigen-matched donor blood in the transfusion management of patients with sickle cell disease. Transfusion 1994;34:562–569.
13. Ambruso DR, Githens JH, Alcorn R, et al. Experience with donors matched for minor blood group antigens in patients with sickle cell anemia who are receiving chronic transfusion therapy. Transfusion 1987;27:94–98.
14. Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusion in children with sickle cell anemia and abnormal results on transcranial doppler ultrasonography. N Engl J Med 1998;339:5–11.
15. Reid ME, Yazdanbakhsh K. Molecular insights into blood groups and implications for blood transfusions. Curr Opin Hematol 1998;5:93–102.
16. Avent ND. Human erythrocyte antigen expression: its molecular bases. Br J Biomed Sci 1997;54:16–37.
17. Rios M, Cash K, Strupp A, Uehlinger J, Reid ME. DNA from urine sediment or buccal cells can be used for blood group molecular genotyping. Immunohematology 1999;15:61–65.
18. Reid ME, Rios M, Powell D, Charles-Pierre D, Malavade V. DNA from blood samples can be used to genotype patients who have recently received a transfusion. Transfusion 2000;40:1–6.
19. Lee S, Wu X, Reid ME, Zelinski T, Redman C. Molecular basis of the Kell (K1) phenotype. Blood 1995;85:912–916.
20. Olivès B, Merriman M, Bailly P, et al. The molecular basis of the Kidd blood group polymorphism and its lack of association with type 1 diabetes susceptibility. Hum Mol Genet 1997;6:1017–1020.
21. Chaudhuri A, Polyakova J, Zbrezeczna V, Williams K, Gulati S, Pogo AO. Cloning of glycoprotein D cDNA, which encodes the major subunit of the Duffy blood group system and the receptor for the Plasmodium vivax malaria parasite. Proc Natl Acad Sci U S A 1993;90:10793–10797.
22. Iwamoto S, Omi T, Kajii E, Ikemoto S. Genomic organization of the glycophorin D gene: Duffy blood group Fy<sup>a</sup>/Fy<sup>b</sup> alloantigen system is associated with a polymorphism at the 44-amino residue. Blood 1995;85:622–626.
23. Simsek S, de Jong CAM, Cuijpers HTHM, et al. Sequence analysis of cDNA derived from reticulocyte mRNAs coding for Rh polypeptides

- and demonstration of E/e and C/c polymorphisms. *Vox Sang* 1994;67:203–209.
24. Castilho LM, Rios M, Pellegrino J Jr, Saad STO, Bianco C, Reid M. A novel point mutation in the erythrocyte Duffy protein. *Transfusion* 1999;39(S)(abstr):S409.
  25. Curtin PD. *Atlantic slave trade: a census*. Milwaukee: University of Wisconsin Press; 1969.
  26. Parasol N, Reid ME, Rios M, Castilho L, Harari I, Kosower NS. A novel mutation in the coding sequence of the FY\*B allele of the Duffy chemokine receptor gene is associated with an altered erythrocyte phenotype. *Blood* 1998;92:2237–2243.
  27. Tournamille C, Collin Y, Cartron J-P, Le Van Kim C. Disruption of a GATA motif in the Duffy gene promotor abolishes erythroid gene expression in Duffy-negative individuals. *Nature Genet* 1995;10:224–228.
  28. Zimmerman PA, Wolley I, Masinde GL, et al. Emergence of FY\*A(null) in a Plasmodium vivax-endemic region of Papua New Guinea. *Proc Natl Acad Sci U S A* 1999;96:13973–13977.
  29. Rios M, Reid ME, Naime D, Chaudhuri A, Pogo AO, Bianco C. Importance of GATA box analysis in genotyping for the Duffy blood group system. *Transfusion* 1997;37(S)(abstr):101S.
  30. Olsson ML, Smythe JS, Hansson C, Akesson IE, Avent ND, Daniels GL. The Fy<sup>x</sup> phenotype is associated with a missense mutation in the Fy<sup>b</sup> predicting Arg89Cys in the Duffy glycoprotein. *Br J Haematol* 1998;103:1184–1191.
  31. Cartron J-P, Bailly P, Le Van Kim C. Insights into the structure and function of membrane polypeptides carrying blood group antigens. *Vox Sang* 1998;74(Supl 2):29–64.
  32. Huang CH. Molecular insights into the Rh protein family and associated antigens. *Curr Opin Hematol* 1997;4:94–103.
  33. Huang CH, Blumenfeld O. MNSs blood groups and major glycoporphins: molecular basis for allelic variation. In: Cartron J-P, Pougher P, editors. *Molecular basis of major human blood group antigens*. New York: Plenum Press; 1995. p 153–183.
  34. Avent ND, Reid ME. The Rh Blood group system: a review. *Blood* 2000;95:1–13.